Literature DB >> 9389989

Structure and function of somatostatin receptors in growth hormone control.

I Shimon1, S Melmed.   

Abstract

This new generation of SRIF analogs offer exciting opportunities to improve hormone hypersecretion in patients with GH- and TSH-secreting pituitary adenomas and possibly even in patients harboring prolactinomas and non-functioning tumors. Future development of novel analogs with improved affinity for both SSTR2 and SSTR5 may have even greater potency to suppress pituitary hormone hypersecretion and block adenoma growth.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9389989

Source DB:  PubMed          Journal:  J Endocrinol        ISSN： 0022-0795            Impact factor:   4.286


  11 in total

1.  Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3.

Authors:  A P Casarini; E M Pinto; R S Jallad; R R Giorgi; D Giannella-Neto; M D Bronstein
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

Review 2.  Synthetic peptides and their non-peptidyl mimetics in endocrinology: from synthesis to clinical perspectives.

Authors:  R Deghenghi
Journal:  J Endocrinol Invest       Date:  1998-12       Impact factor: 4.256

3.  Expression of somatostatin receptor subtype 2 in growth hormone-secreting pituitary adenoma and the regulation of miR-185.

Authors:  X Fan; Z Mao; D He; C Liao; X Jiang; N Lei; B Hu; X Wang; Z Li; Y Lin; X Gou; Y Zhu; H Wang
Journal:  J Endocrinol Invest       Date:  2015-06-03       Impact factor: 4.256

4.  The association of pituitary tumors and headache.

Authors:  Miles J Levy
Journal:  Curr Neurol Neurosci Rep       Date:  2011-04       Impact factor: 5.081

Review 5.  New medical treatment for acromegaly.

Authors:  A J van der Lely; W W de Herder; S W Lamberts
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

6.  Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2.

Authors:  L Yang; S C Berk; S P Rohrer; R T Mosley; L Guo; D J Underwood; B H Arison; E T Birzin; E C Hayes; S W Mitra; R M Parmar; K Cheng; T J Wu; B S Butler; F Foor; A Pasternak; Y Pan; M Silva; R M Freidinger; R G Smith; K Chapman; J M Schaeffer; A A Patchett
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

7.  Efficacy of long-term lanreotide treatment in patients with acromegaly.

Authors:  Yoel Toledano; Liat Rot; Yona Greenman; Sophia Orlovsky; Yulia Pauker; David Olchovsky; Achia Eliash; Orit Bardicef; Ofa Makhoul; Gloria Tsvetov; Michal Gershinsky; Odile Cohen-Ouaqnine; Rosane Ness-Abramof; Zaina Adnan; Jacob Ilany; Hadassah Guttmann; Mazal Sapir; Carlos Benbassat; Ilan Shimon
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

8.  Somatostatin-14 influences pituitary-ovarian axis in peripubertal rats.

Authors:  Natasa Nestorović; Milica Manojlović-Stojanoski; Natasa Ristić; Milka Sekulić; Branka Sosić-Jurjević; Branko Filipović; Verica Milosević
Journal:  Histochem Cell Biol       Date:  2008-05-21       Impact factor: 4.304

9.  Decreased insulin requirements after LAR-octreotide but not after lanreotide in an acromegalic patient.

Authors:  S M Webb; E Ortega; J Rodríguez-Espinosa; M E Mato; R Corcoy
Journal:  Pituitary       Date:  2001-09       Impact factor: 4.107

Review 10.  Somatostatin analogs as primary medical therapy for acromegaly.

Authors:  Ann Danoff; David Kleinberg
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.925
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.